Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 642141, 8 pages
http://dx.doi.org/10.5402/2012/642141
Review Article

Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer

1Molecular and Cell Biology Program, Ohio University, Athens, OH, USA
2Biomedical Engineering Program, Russ College of Engineering and Technology, Ohio University, Athens, OH, USA
3Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, OH, USA

Received 20 October 2011; Accepted 10 November 2011

Academic Editors: D. Mezzanzanica, A. E. Pinto, and M. J. Turk

Copyright © 2012 Maria Muccioli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Cannistra, “Cancer of the ovary,” New England Journal of Medicine, vol. 351, no. 24, pp. 2519–2565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Shah and G. K. Schwartz, “Cell cycle-mediated drug resistance: an emerging concept in cancer therapy,” Clinical Cancer Research, vol. 7, no. 8, pp. 2168–2181, 2001. View at Google Scholar · View at Scopus
  3. T. H. Mogensen, “Pathogen recognition and inflammatory signaling in innate immune defenses,” Clinical Microbiology Reviews, vol. 22, no. 2, pp. 240–273, 2009. View at Publisher · View at Google Scholar
  4. K. Takeda and S. Akira, “Roles of Toll-like receptors in innate immune responses,” Genes to Cells, vol. 6, no. 9, pp. 733–742, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Kapsenberg, “Dendritic-cell control of pathogen-driven T-cell polarization,” Nature Reviews Immunology, vol. 3, no. 12, pp. 984–993, 2003. View at Google Scholar · View at Scopus
  6. R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Arroyo and M. L. Iruela-Arispe, “Extracellular matrix, inflammation, and the angiogenic response,” Cardiovascular Research, vol. 86, no. 2, pp. 226–235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Feldmann and R. N. Maini, “Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies,” Joint Bone Spine, vol. 69, no. 1, pp. 12–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Rüegg, “Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions,” Journal of Leukocyte Biology, vol. 80, no. 4, pp. 682–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. W. W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Nelson and R. Ganss, “Tumor growth or regression: powered by inflammation,” Journal of Leukocyte Biology, vol. 80, no. 4, pp. 685–690, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Li and I. M. Verma, “NF-κB regulation in the immune system,” Nature Reviews Immunology, vol. 2, no. 10, pp. 725–734, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Karin, Y. Cao, F. R. Greten, and Z. W. Li, “NF-κB in cancer: from innocent bystander to major culprit,” Nature Reviews Cancer, vol. 2, no. 4, pp. 301–310, 2002. View at Google Scholar · View at Scopus
  16. B. Salaun, I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno, “TLR3 can directly trigger apoptosis in human cancer cells,” Journal of Immunology, vol. 176, no. 8, pp. 4894–4901, 2006. View at Google Scholar · View at Scopus
  17. K. Takeda and S. Akira, “TLR signaling pathways,” Seminars in Immunology, vol. 16, no. 1, pp. 3–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. D. Killeen, J. H. Wang, E. J. Andrews, and H. P. Redmond, “Exploitation of the toll-like receptor system in cancer: a doubled-edged sword?” British Journal of Cancer, vol. 95, no. 3, pp. 247–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Huang, J. Zhao, J. C. Unkeless, Z. H. Feng, and H. Xiong, “TLR signaling by tumor and immune cells: a double-edged sword,” Oncogene, vol. 27, no. 2, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Zheng, P. A. Cohen, C. A. Paustian et al., “Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12,” Cancer Research, vol. 68, no. 11, pp. 4045–4049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. E. I. Cho, C. Tan, G. K. Koski, P. A. Cohen, S. Shu, and W. T. Lee, “Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines,” Head and Neck, vol. 32, no. 6, pp. 700–707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Ma, J. Zhang, J. Zhang, and C. Zhang, “The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice,” Cellular & Molecular Immunology, vol. 7, no. 5, pp. 381–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. Prins, N. Craft, K. W. Bruhn et al., “The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity,” Journal of Immunology, vol. 176, no. 1, pp. 157–164, 2006. View at Google Scholar · View at Scopus
  24. S. M. Amos, H. J. Pegram, J. A. Westwood et al., “Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice,” Cancer Immunology, Immunotherapy, vol. 60, no. 5, pp. 671–683, 2011. View at Publisher · View at Google Scholar
  25. C. Brignole, D. Marimpietri, D. Di Paolo et al., “Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma,” Cancer Research, vol. 70, no. 23, pp. 9816–9826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Thuringer, A. Hammann, N. Benikhlef et al., “Transactivation of the epidermal growth factor receptor by heat shock protein 90 via toll-like receptor 4 contributes to the migration of glioblastoma cells,” Journal of Biological Chemistry, vol. 286, no. 5, pp. 3418–3428, 2011. View at Publisher · View at Google Scholar
  27. J. Cherfils-Vicini, S. Platonova, M. Gillard et al., “Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1285–1297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Chiron, C. Pellat-Deceunynck, M. Amiot, R. Bataille, and G. Jego, “TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production,” Journal of Immunology, vol. 182, no. 7, pp. 4471–4478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Coukos, M. C. Courreges, and F. Benencia, “Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm,” Current Gene Therapy, vol. 3, no. 2, pp. 113–125, 2003. View at Google Scholar · View at Scopus
  30. M. A. Nash, G. Ferrandina, M. Gordinier, A. Loercher, and R. S. Freedman, “The role of cytokines in both the normal and malignant ovary,” Endocrine-Related Cancer, vol. 6, no. 1, pp. 93–107, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. A. D. Santin, P. L. Hermonat, A. Ravaggi, M. J. Cannon, S. Pecorelli, and G. P. Parham, “Secretion of vascular endothelial growth factor in ovarian cancer,” European Journal of Gynaecological Oncology, vol. 20, no. 3, pp. 177–181, 1999. View at Google Scholar · View at Scopus
  32. K. D. Elgert, D. G. Alleva, and D. W. Mullins, “Tumor-induced immune dysfunction: the macrophage connection,” Journal of Leukocyte Biology, vol. 64, no. 3, pp. 275–290, 1998. View at Google Scholar · View at Scopus
  33. D. I. Gabrilovich, T. Ishida, S. Nadaf, J. E. Ohm, and D. P. Carbone, “Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function,” Clinical Cancer Research, vol. 5, no. 10, pp. 2963–2970, 1999. View at Google Scholar · View at Scopus
  34. T. J. Curiel, P. Cheng, P. Mottram et al., “Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer,” Cancer Research, vol. 64, no. 16, pp. 5535–5538, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Mantovani, S. Sozzani, M. Locati et al., “Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Novartis Foundation Symposium, vol. 256, pp. 137–145, 2004. View at Google Scholar · View at Scopus
  36. G. Coukos, F. Benencia, R. J. Buckanovich, and J. R. Conejo-Garcia, “The role of dendritic cell precursors in tumour vasculogenesis,” British Journal of Cancer, vol. 92, no. 7, pp. 1182–1187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Conejo-Garcia, R. J. Buckanovich, F. Benencia et al., “Vascular leukocytes contribute to tumor vascularization,” Blood, vol. 105, no. 2, pp. 679–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Huarte, J. R. Cubillos-Ruiz, Y. C. Nesbeth et al., “Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity,” Cancer Research, vol. 68, no. 18, pp. 7684–7691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Y. Woo, C. S. Chu, T. J. Goletz et al., “Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer,” Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001. View at Google Scholar · View at Scopus
  40. T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. R. J. Buckanovich, A. Facciabene, S. Kim et al., “Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy,” Nature Medicine, vol. 14, no. 1, pp. 28–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Bourquin, C. Wurzenberger, S. Heidegger et al., “Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response,” Journal of Immunotherapy, vol. 33, no. 9, pp. 935–944, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. R. Cubillos-Ruiz, X. Engle, U. K. Scarlett et al., “Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity,” Journal of Clinical Investigation, vol. 119, no. 8, pp. 2231–2244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. U. K. Scarlett, J. R. Cubillos-Ruiz, Y. C. Nesbeth et al., “In situ stimulation of CD40 and toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells,” Cancer Research, vol. 69, no. 18, pp. 7329–7337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Zhou, M. M. McFarland-Mancini, H. M. Funk, N. Husseinzadeh, T. Mounajjed, and A. F. Drew, “Toll-like receptor expression in normal ovary and ovarian tumors,” Cancer Immunology, Immunotherapy, vol. 58, no. 9, pp. 1375–1385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. C. Woods, Y. A.R. White, C. Dau, and A. L. Johnson, “TLR4 activates NF-κB in human ovarian granulosa tumor cells,” Biochemical and Biophysical Research Communications, vol. 409, no. 4, pp. 675–680, 2011. View at Publisher · View at Google Scholar
  48. R. Berger, H. Fiegl, G. Goebel et al., “Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors,” Cancer Science, vol. 101, no. 4, pp. 1059–1066, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Szajnik, M. J. Szczepanski, M. Czystowska et al., “TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer,” Oncogene, vol. 28, no. 49, pp. 4353–4363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. G. Kelly, A. B. Alvero, R. Chen et al., “TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer,” Cancer Research, vol. 66, no. 7, pp. 3859–3868, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. C. Wang, Q. B. Su, F. X. Wu, X. L. Zhang, and P. S. Liu, “Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells,” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 157–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Seya and M. Matsumoto, “The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1175–1184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Hirano, K. Ishihara, and M. Hibi, “Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors,” Oncogene, vol. 19, no. 21, pp. 2548–2556, 2000. View at Google Scholar · View at Scopus
  54. Y. Nesbeth, U. Scarlett, J. Cubillos-Ruiz et al., “CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion,” Cancer Research, vol. 69, no. 15, pp. 6331–6338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. J. R. Cubillos-Ruiz, S. Fiering, and J. R. Conejo-Garcia, “Nanomolecular targeting of dendritic cells for ovarian cancer therapy,” Future Oncology, vol. 5, no. 8, pp. 1189–1192, 2009. View at Publisher · View at Google Scholar · View at Scopus